BLA 761036 · Janssen Biotech
Darzalex
Daratumumab · Injection · CD38-directed Cytolytic Antibody
NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: May 28, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2015
Nov 16, 2015
Approved uses
15
Original approval plus efficacy supplements
Registered trials
426
89 Phase 3, 109 recruiting
FAERS reports
40,859
34,641 serious, 5,117 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 10, 2026.
DARZALEX is indicated for the treatment of adult patients with multiple myeloma: in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy. in combination with bortezomib, melphalan and prednisone in newly diagnosed patients who are ineligible for autologous stem cell transplant. in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant. in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy. in combination with carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy. in combination with pomalidomide and dexamethasone in patients who have received at least two prior therapies including lenalidomide and a proteasome inhibitor. as monotherapy, in patients who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent. DARZALEX is a CD38-directed cytolytic antibody indicated for the treatment of adult patients with multiple myeloma: in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy in combination with bortezomib, melphalan and prednisone in newly diagnosed patients who are ineligible for autologous stem cell transplant in combination with bortezomib, thalidomide,...
Mechanism: CD38 is a transmembrane glycoprotein (48 kDa) expressed on the surface of hematopoietic cells, including multiple myeloma and other cell types and tissues and has multiple functions, such as receptor mediated adhesion, signaling, and modulation of cyclase and hydrolase activity. Daratumumab is an IgG1κ human monoclonal antibody (mAb) that binds to CD38 and inhibits the growth of CD38 expressing tumor cells by inducing apoptosis directly through Fc mediated cross linking as well as by immune-mediated tumor cell lysis through complement dependent cytotoxicity (CDC), antibody dependent cell...
Therapeutic areas: Hematology and blood cancers
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 10, 2025 Supplement 54 · Efficacy OrphanLetterLabel
- Jan 23, 2025 Supplement 51 · Efficacy OrphanLabelLetter
- Jul 31, 2024 Supplement 50 · Efficacy OrphanLetterLabel
- Jan 19, 2023 Supplement 44 · Efficacy OrphanLabelLetter
- Mar 4, 2022 Supplement 41 · Efficacy OrphanLetterLabel
- Aug 20, 2020 Supplement 29 · Efficacy OrphanLabelLetter
- Jun 29, 2020 Supplement 26 · Efficacy OrphanLabelLetter
- Sep 26, 2019 Supplement 24 · Efficacy · priority review OrphanLabelLetter
- Jun 27, 2019 Supplement 20 · Efficacy · priority review OrphanLabelLetter
- Feb 8, 2019 Supplement 16 · Efficacy OrphanLabelLetter
- May 7, 2018 Supplement 13 · Efficacy · priority review OrphanLetterLabel
- Jun 16, 2017 Supplement 5 · Efficacy OrphanLabelLetter
- Nov 21, 2016 Supplement 4 · Efficacy · priority review Breakthrough therapyOrphanLabelLetter
- Nov 21, 2016 Supplement 3 · Efficacy · priority review Breakthrough therapyOrphanLetterLabel
- Nov 16, 2015 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalOrphanReviewLetterLabel
2 products under this application
- DARZALEX · DARATUMUMAB 400MG/20ML · INJECTABLE, INJECTION · Prescription
- DARZALEX · DARATUMUMAB 100MG/5ML · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Daratumumab" as an intervention, any sponsor and status, largest first.
- Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)Pivotal-lookingNot yet recruiting
Children's Oncology GroupResearch network
NCT07072585 · 1,708 participants (planned) · Start Aug 28, 2026 · Primary completion Sep 1, 2035
Drug: Bortezomib; Calaspargase Pegol and 16 more · For: Stage II T Lymphoblastic Leukemia/Lymphoma; Stage III T Lymphoblastic Leukemia/Lymphoma; Stage IV T Lymphoblastic Leukemia/Lymphoma and 2 more
- A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple MyelomaPivotal-lookingRecruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT05552222 · 1,590 participants (planned) · Start Oct 25, 2022 · Primary completion Apr 30, 2031
Drug: Teclistamab; Daratumumab and 3 more · For: Multiple Myeloma
Sites: Gilbert, Arizona; Tucson, Arizona; Clovis, California · 270 sites in all
- Pan Tumor Rollover StudyRecruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT03899155 · 1,500 participants (planned) · Start Aug 9, 2019 · Primary completion Aug 25, 2029
Drug: Nivolumab; Ipilimumab and 17 more · For: Cancer
Sites: Huntsville, Alabama; Tucson, Arizona; Lynwood, California · 410 sites in all
- Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE TrialPivotal-lookingRecruiting
ECOG-ACRIN Cancer Research GroupResearch network
NCT04566328 · 1,450 participants (planned) · Start Feb 24, 2021 · Primary completion Dec 31, 2027
Drug: Bortezomib; Daratumumab and Hyaluronidase-fihj and 2 more · For: Plasma Cell Myeloma; RISS Stage I Plasma Cell Myeloma; RISS Stage II Plasma Cell Myeloma
Sites: Anchorage, Alaska; Phoenix, Arizona; Tucson, Arizona · 647 sites in all
- Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness LevelPivotal-lookingRecruiting
University of LeedsAcademic, hospital or other
NCT07649525 · 1,226 participants (planned) · Start Jul 3, 2026 · Primary completion Jun 2033
Drug: Daratumumab; Lenalidomide and 3 more · For: Multiple Myeloma (MM); Plasma Cell Leukemia (PCL)
Sites: Bristol, United Kingdom; Eastbourne, United Kingdom; Leeds, United Kingdom · 5 sites in all
- S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy DurationPivotal-lookingActive, not recruiting
SWOG Cancer Research NetworkResearch network
NCT04071457 · 1,100 participants (planned) · Start Aug 13, 2019 · Primary completion Sep 2032
Drug: Lenalidomide; Daratumumab/rHuPH20 · For: Multiple Myeloma
Sites: Anchorage, Alaska; Fairbanks, Alaska; Kingman, Arizona · 842 sites in all
- A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple MyelomaPivotal-lookingCompleted
Intergroupe Francophone du MyelomeResearch network
NCT02541383 · 1,085 participants · Start Sep 2015 · Primary completion Aug 27, 2020
Drug: Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD); Bortezomib, Thalidomide, Dexamethasone (VTD) + daratumumab and 1 more · For: Multiple Myeloma
Sites: Antwerp, Belgium; Bruges, Belgium; Brussels, Belgium · 107 sites in all
PfizerPfizer (PFE)
NCT05623020 · 1,060 participants (planned) · Start Nov 10, 2022 · Primary completion Oct 18, 2030
Drug: Elranatamab; Daratumumab and 3 more · For: Multiple Myeloma
Sites: Daphne, Alabama; Fairhope, Alabama; Mobile, Alabama · 180 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- plasma cell myeloma3,989
- off label use3,646
- infusion related reaction2,692
- neutropenia2,082
- pneumonia2,065
- fatigue1,795
- diarrhoea1,784
- drug ineffective1,636
- neuropathy peripheral1,500
- death1,490
- thrombocytopenia1,445
- pyrexia1,348
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2014 | 5 |
| 2015 | 83 |
| 2016 | 1,385 |
| 2017 | 1,850 |
| 2018 | 2,874 |
| 2019 | 3,460 |
| 2020 | 3,566 |
| 2021 | 4,289 |
| 2022 | 5,045 |
| 2023 | 5,625 |
| 2024 | 5,286 |
| 2025 | 4,105 |
| 2026 | 3,286 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Darzalex (Daratumumab)
2024 spending
$18.0M
Beneficiaries
201
1,702 claims
Per beneficiary
$89,577
$139.46 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $20,308,290 |
| 2021 | $14,704,062 |
| 2022 | $15,850,768 |
| 2023 | $16,069,467 |
| 2024 | $18,004,962 |
Part B: Darzalex (Daratumumab) · HCPCS J9145
2024 spending
$150M
Beneficiaries
2,246
19,505 claims
Per beneficiary
$66,731
2024 ASP limit $63.08 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $837,409,111 |
| 2021 | $478,628,176 |
| 2022 | $318,319,113 |
| 2023 | $221,722,229 |
| 2024 | $149,876,829 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Sonneveld P, Dimopoulos MA, Boccadoro M, et al. · N Engl J Med 2024 · Clinical Trial, Phase III, Randomized Controlled Trial
- Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma.
Costa LJ, Bahlis NJ, Perrot A, et al. · N Engl J Med 2026 · Randomized Controlled Trial, Clinical Trial, Phase III
- Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial.
Usmani SZ, Facon T, Hungria V, et al. · Nat Med 2025 · Clinical Trial, Phase III, Randomized Controlled Trial
- Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma.
Hungria V, Robak P, Hus M, et al. · N Engl J Med 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma.
Dimopoulos MA, Voorhees PM, Schjesvold F, et al. · N Engl J Med 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
Kastritis E, Palladini G, Minnema MC, et al. · N Engl J Med 2021 · Clinical Trial, Phase III, Comparative Study
Sponsor: Johnson & Johnson (Janssen)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.